Arvinas Doses First Patient in ARV-6723 Phase 1/2 Trial
NEW HAVEN, Conn. — September 28, 2026 Arvinas, Inc. announced that the first participant has been dosed in the...
Protein Degradation
Advertisement
Prelude Therapeutics Gains FDA Clearance for PRT13722
WILMINGTON, Del. — September 10, 2026 Prelude Therapeutics Incorporated announced that the U.S. Food and Drug Administration (FDA) has...
Monte Rosa Advances MRT-6160 Into Phase 2 for Sjögren’s Disease
BOSTON, Massachusetts — September 8, 2026 Monte Rosa Therapeutics, Inc. announced that Novartis has initiated a global Phase 2...
Rigel Launches VEPPANU for ESR1-Mutated Breast Cancer
South San Francisco, California, August 13, 2026 Rigel Pharmaceuticals, Inc. announced the U.S. commercial availability of VEPPANU™ (vepdegestrant) for...
Dianthus Unveils DNTH312 Dual-Target Autoimmune Therapy
NEW YORK and WALTHAM, Mass., August 4, 2026 Dianthus Therapeutics, Inc. announced the launch of DNTH312, an internally developed...
Advertisements
Nurix and Sanofi Advance Oral STAT6 Degrader into Phase 1 Clinical Development
BRISBANE, Calif., August 4, 2026 Nurix Therapeutics, Inc. announced it has earned a $10 million development milestone payment after...
Biohaven and Yale Secure Major Win in MODA Technology Dispute
NEW HAVEN, Conn., July 27, 2026 Biohaven Ltd. and Yale University have secured a significant legal victory after a...
Monte Rosa and Novartis Expand Degrader Alliance in Immunology
BOSTON, Mass., September 15, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company pioneering molecular glue...
Advertisement
